Literature DB >> 6939954

Endogenous glucose production in Type I glycogen storage disease.

R C Powell, S M Wentworth, I K Brandt.   

Abstract

The adaptive mechanisms that protect some patients with Type I glycogen storage disease from fasting hypoglycemia were examined in two young adults. Both maintained low normal fasting plasma glucose concentrations even during 3 day fasts; blood lactate concentrations increased during the first 12 hr and then decreased to normal during the second and third days. Acute hyperglycemic responses to glucagon nearly doubled after three days of starvation when compared with responses following 12 hr fasts. Enhanced glucagon-induced hyperglycemic changes also were observed following the administration of alcohol or glucocorticoids. However, fructose infusions failed to demonstrate hyperglycemic responses after a 3 day fast, alcohol or glucocorticoids. The present studies demonstrate endogenous glucose production in our patients despite an absence of the enzyme glucose-6-phosphatase. These findings could explain why some patients with Type I glycogen storage disease are protected from fasting hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6939954     DOI: 10.1016/0026-0495(81)90178-5

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

Review 1.  Flux analysis of inborn errors of metabolism.

Authors:  D-J Reijngoud
Journal:  J Inherit Metab Dis       Date:  2018-01-09       Impact factor: 4.982

2.  SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a case report.

Authors:  Daisuke Katayama; Hiroo Baba; Takashige Kuwabara; Jun Kido; Hiroshi Mitsubuchi; Shirou Matsumoto; Kimitoshi Nakamura
Journal:  J Med Case Rep       Date:  2021-02-16

Review 3.  Dynamic Methods for Childhood Hypoglycemia Phenotyping: A Narrative Review.

Authors:  Alessandro Rossi; Martijn G S Rutten; Theo H van Dijk; Barbara M Bakker; Dirk-Jan Reijngoud; Maaike H Oosterveer; Terry G J Derks
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.